港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

613.394

-8.170-1.31%

涨家数：9

跌家数：24

平家数：1

市盈率：- -

高：630.328

开：622.736

低：612.007

收：621.564

成交量：7,335.13万

成交额：17.71亿

市值：3,918.07亿

流通市值：3,502.24亿

数据加载中...

总览新闻资讯

转型向“智”拓市向“云” 衡水冀州以数智赋能工业发展

中国新闻网

152亿美元！恒瑞为何能让全球制药巨头疯狂？

21世纪经济报道

欧康维视生物-B(01477)授出购股权及奖励

加科思-B(01167)5月12日斥资46.6万港元回购7.89万股

贝康医疗-B(02170)拟实施H股全流通计划

归创通桥(02190.HK)5月12日耗资113.6万港元回购5.1万股

创新药再爆百亿BD大单！华宝基金药ETF逆市连阳！多头提前埋伏，连续4日爆买520880！

GIC Private Limited增持歌礼制药-B(01672)12.2万股每股作价16.612港元

斥资7亿，“果蔬第一股”玩医药，新控股股东能否力挽狂澜？

再鼎医药(09688)：授出购股权及受限制股份单位

国泰海通：1Q26行业趋势延续向好创新药仍是医药板块景气主线

微创心通－Ｂ(02160)股价下跌5.328%，现价港币$2.31

阿斯达克财经

利好突袭！3800亿巨头直线拉升，百亿美元大单引爆创新药概念

21世纪经济报道

黑永疆离开石药创业，医药老兵“第三阶段”想干什么？

21世纪经济报道

创新药概念局部异动

恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药

老虎资讯综合

《大行》摩通：医保目录调整加速创新药商业化首选信达生物(01801.HK)药明康德(02359.HK)药明合联(02268.HK)科伦博泰(06990.HK)

阿斯达克财经

北京亦庄牵头编制医疗器械、自动驾驶数据出境负面清单

港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定

中泰证券医疗器械2025及2026Q1总结：负面扰动逐步出清持续看好创新驱动与全球化

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":613.3937,"timestamp":1778573281394,"preClose":621.5637,"halted":0,"volume":73351330,"delay":0,"changeRate":-0.013144,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-8.170044,"latestTime":"05-12 16:00:00","open":622.73566,"high":630.3282,"low":612.00696,"amount":1771388643,"amplitude":0.029476,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1778549400000,1778558400000],[1778562000000,1778572800000]],"pbRate":4.803894,"peRate":-90.711909,"turnoverRate":0.002622,"increases":9,"decrements":24,"flats":0,"marketCap":391806966464,"floatMarketCap":350224467920},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":630.3282,"amplitude":0.029476,"preClose":621.5637,"low":612.00696,"pbRate":"4.803894","latestPrice":613.3937,"volume":73351330,"delay":0,"open":622.73566,"prevYearClose":556.26263,"prevWeekClose":624.992,"prevMonthClose":639.5,"prevQuarterClose":610.821,"fiveDayClose":621.508,"twentyDayClose":666.858,"sixtyDayClose":539.786,"secType":"PLATE","market":"HK","turnoverRate":0.002622,"peRate":-90.711909,"marketCap":391806966464,"floatMarketCap":350224467920,"timestamp":1778573281394,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":9,"down":24,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634774210","title":"转型向“智”拓市向“云” 衡水冀州以数智赋能工业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2634774210","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634774210?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 22:18","pubTimestamp":1778595480,"startTime":"0","endTime":"0","summary":"中新网衡水5月12日电 题：转型向“智”拓市向“云” 衡水冀州以数智赋能工业发展作者 李玉素 谌诗雨 王鹏“大家现在看到的是我们专为失能、半失能老人推出的多功能护理床，背腿联动、一键操作，大大减轻家人照护压力。”李玉素 摄这是河北省衡水市冀州区推进 “一品一播” 行动、以数智赋能工业发展的日常场景。如今，该企业依托冀州区“一品一播”基地大力开拓市场，实现内外销双向发力、协同增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-12/doc-inhxsawi5099302.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-12/doc-inhxsawi5099302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1100","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634107952","title":"152亿美元！恒瑞为何能让全球制药巨头疯狂？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634107952","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634107952?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 22:11","pubTimestamp":1778595060,"startTime":"0","endTime":"0","summary":"5月12日午盘，恒瑞医药突然放出一枚深水炸弹：和全球制药巨头百时美施贵宝（BMS）达成了重磅合作！这笔买卖到底有多大？潜在总交易额高达152亿美元！BMS先支付9.5亿美元首付和近期付款，后面只要药物研发能顺利推下去，恒瑞还能拿到上百亿的里程碑付款，甚至未来的销售分成！这次合作涉及13款早期创新药，主攻肿瘤、血液和免疫疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734849437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734849437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634212162","title":"欧康维视生物-B(01477)授出购股权及奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634212162?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 21:26","pubTimestamp":1778592417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，董事会认为有必要实施激励措施以支持本集团的战略增长目标，并维持人才招聘及留任方面的竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634214323","title":"加科思-B(01167)5月12日斥资46.6万港元回购7.89万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634214323","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634214323?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 20:57","pubTimestamp":1778590679,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年5月12日斥资46.6万港元回购7.89万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219560","title":"贝康医疗-B(02170)拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219560","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219560?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 20:09","pubTimestamp":1778587773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B(02170)公布，董事会已审议及批准建议实施H股全流通，以转换合共约1.91亿股公司未上市股份为公司H股。待取得所有相关批准及╱或备案(包括中国证监会的备案通知及联交所的批准)并符合所有适用法律、法规及规则后，该等未上市股份将转换为H股，且公司将申请批准该等H股于联交所主板上市及买卖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK1597","02170","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216688","title":"归创通桥(02190.HK)5月12日耗资113.6万港元回购5.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216688","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216688?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 19:47","pubTimestamp":1778586424,"startTime":"0","endTime":"0","summary":"格隆汇5月12日丨归创通桥(02190.HK)公告，5月12日耗资113.6万港元回购5.1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260512/32218487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02190","BK1583","BK1587","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634215477","title":"创新药再爆百亿BD大单！华宝基金药ETF逆市连阳！多头提前埋伏，连续4日爆买520880！","url":"https://stock-news.laohu8.com/highlight/detail?id=2634215477","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634215477?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 19:38","pubTimestamp":1778585880,"startTime":"0","endTime":"0","summary":"5月12日，AH创新药整体延续调整。午间恒瑞医药官宣重磅BD，其A股暴拉涨停，H股一度冲涨16%，带动板块直线拉升翻红。　　A股制药板块午后自深水区拉起，场内唯一药ETF华宝*直线冲高1.73%根据PCF清单，恒瑞医药为药ETF华宝第一大权重股，最新权重占比14.13%。　　截至收盘，药ETF华宝逆市收涨，成功连阳站上10日线。2026年一季度，中国创新药对外BD的平均首付款为1.8亿美元，相比2025年增长59%，相比5年前更是大涨187%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-05-12/doc-inhxrwqe1459758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","520880","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021349","title":"GIC Private Limited增持歌礼制药-B(01672)12.2万股 每股作价16.612港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021349","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634021349?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 19:07","pubTimestamp":1778584055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月7日，GIC Private Limited增持歌礼制药-B(01672)12.2万股，每股作价16.612港元，总金额约为202.67万港元。增持后最新持股数目为7480.8万股，最新持股比例为7.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1191","BK1161","GIC","BK4104","BK1574","EWH","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634724291","title":"斥资7亿，“果蔬第一股”玩医药，新控股股东能否力挽狂澜？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634724291","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634724291?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 17:08","pubTimestamp":1778576880,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　它就是有着“果蔬第一股”之称的宏辉果蔬。　　近期，宏辉果蔬发布公告，拟斥资7亿元收购江西施美药业41.128%股权，完成收购后，施美药业将成为宏辉果蔬控股子公司，并表进入上市公司。2016年公司在上交所上市，成为资本市场备受瞩目的“果蔬第一股”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-12/doc-inhxrshk9915717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634299314","title":"再鼎医药(09688)：授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2634299314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634299314?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 16:34","pubTimestamp":1778574847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划授出13.68万份购股权(以美国存托股份计)、7.53万份受限制股份单位(以美国存托股份计)。所授出购股权涉及的相关股份数目：1,368,190;所授出受限制股份单位涉及的相关股份数目：752,880。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4531","BK4588","LU2488822045.USD","09688","BK1161","BK4548","ZLAB","BK4526","BK4585","BK1588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634295796","title":"国泰海通：1Q26行业趋势延续向好 创新药仍是医药板块景气主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2634295796","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634295796?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 15:57","pubTimestamp":1778572645,"startTime":"0","endTime":"0","summary":"创新药销售与BD收入形成双轮驱动，行业增长结构持续优化2025年药企创新药相关收入，即创新药销售收入与BD收入合计约1940亿元，同比+35%，占药品板块总收入比例已提升至42%。商业化Biotech受益于收入规模快速扩大，销售费用率明显摊薄，盈利拐点进一步明确。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1564","BK1161","BK0201","02611","BK0012","159938","BK0028","BK0276","BK1515","159992","09939","BK0184","BK0183","BK1147","06978","BK1574","601211","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634341260","title":"微创心通－Ｂ(02160)股价下跌5.328%，现价港币$2.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2634341260","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634341260?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 14:35","pubTimestamp":1778567700,"startTime":"0","endTime":"0","summary":"[下跌股]微创心通－Ｂ(02160) 股价在下午02:35比前收市价下跌5.328%，现股价为港币$2.31。至目前为止，今日最高价为$2.45，而最低价为$2.31。总成交量为75.72万股，总成交金额为港币$177.724万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605122231/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605122231/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","02160","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634625572","title":"利好突袭！3800亿巨头直线拉升，百亿美元大单引爆创新药概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2634625572","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634625572?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 14:14","pubTimestamp":1778566440,"startTime":"0","endTime":"0","summary":"5月12日，创新药概念局部异动。其中，恒瑞医药（600276.SH）午后直线拉涨，随后回落，截至13:35，报56.61元/股，涨5.77%，总市值3757亿元；重药控股（000950.SZ）、津药药业（600488.SH）涨停，华兰股份（301093.SZ）、成都先导（688222.SH）等多只概念股涨超5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734373335.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734373335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634584262","title":"黑永疆离开石药创业，医药老兵“第三阶段”想干什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634584262","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634584262?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 14:10","pubTimestamp":1778566200,"startTime":"0","endTime":"0","summary":"5月6日，工信部刚刚公布了石药集团入选2025年数字化转型典型案例的消息。然而就在几天之后，这艘老牌航母刚刚完成“航母+AI”的华丽转身，正朝着创新药全球化全力调头之际，又一则重磅消息搅动了整个生物医药圈。　　市场消息显示，石药集团执行总裁、全球首席医学官黑永疆博士，已从石药集团正式离职，创立上海慧思博生物医药科技有限公司。　　企业信息显示，慧思博生物成立于2026年4月13日，注册资本500万元，位于上海青浦区。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0314109678.HKD","LU2039709279.SGD","LU0315179316.USD","LU1226288170.HKD","LU1328277881.USD","LU0140636845.USD","BK1521","LU1813983027.USD","LU1960683339.HKD","BK1574","LU0880133367.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU1152091168.USD","LU1226287875.USD","LU1807302812.USD","LU0067412154.USD","LU1951186391.HKD","LU0072913022.USD","IE0008368742.USD","LU0501845795.SGD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YT58.USD","LU1993786604.SGD","SG9999004220.SGD","BK1161","LU1226287792.SGD","LU1226288253.USD","HK0000165453.HKD","LU1152091754.HKD","BK1515","BK1191","IE0008369823.USD","IE00B543WZ88.USD","159938","161022","LU0326950275.SGD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","01093","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634269896","title":"创新药概念局部异动","url":"https://stock-news.laohu8.com/highlight/detail?id=2634269896","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634269896?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 13:07","pubTimestamp":1778562453,"startTime":"0","endTime":"0","summary":"创新药概念局部异动","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734314845.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734314845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198821818","title":"恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1198821818","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198821818?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 13:03","pubTimestamp":1778562223,"startTime":"0","endTime":"0","summary":"5月12日，$恒瑞医药(01276)$午后直线拉升，一度涨超16%！该公司与BMS达成全球重磅合作，携手开发13款早期创新药。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2580892789.USD","BK0012","BMY","LU2289578879.USD","LU1655091616.SGD","LU1997245094.SGD","BK1161","LU1064130708.USD","LU0359201885.HKD","159992","BK1191","LU2097828631.EUR","LU1146622755.USD","LU0405327494.USD","LU1064131003.USD","LU2495084118.USD","LU2580892862.HKD","LU2148510915.USD","LU1023057109.AUD","BK0183","LU0405327148.USD","BK1574","LU2097828805.USD","BK0188","01276","LU1580142542.USD","LU1781817850.SGD","LU2097828714.EUR","LU2097828474.EUR","LU1997244956.HKD","LU0359202008.SGD","LU2097828557.USD","BK0028","BK0060","BK0196","LU1255011170.USD","LU1328615791.USD","LU0359201612.USD","LU2328871848.SGD","LU1820825898.SGD","BK0239","LU1997245177.USD","LU1969619763.USD","LU2543165471.USD","LU2488822045.USD","600276"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2634636272","title":"《大行》摩通：医保目录调整加速创新药商业化  首选信达生物(01801.HK)药明康德(02359.HK)药明合联(02268.HK)科伦博泰(06990.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634636272","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634636272?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 11:49","pubTimestamp":1778557740,"startTime":"0","endTime":"0","summary":"报告指出，商业保险至国家医保目录的桥接路径正式确立，验证了许多创新药公司一直追求的双重清单策略。目前被商业保险覆盖但未纳入国家医保目录的药物，因零售价过往超出医保谈判的接受范围，新规对此类药物尤其有意义。摩根大通重申对信达生物、科伦博泰、药明康德及药明合联的正面看法，并将其列为行业首选股。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1524013/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1524013/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","LU1979443071.USD","LU0502904849.HKD","01801","LU0348766576.USD","LU2097828557.USD","LU2097828714.EUR","LU1969619763.USD","LU1046422090.SGD","LU2495084118.USD","LU1719994722.HKD","LU0052750758.USD","LU1303224171.USD","LU1997244956.HKD","LU0708995583.HKD","LU2097828474.EUR","LU2125910500.SGD","LU0196878994.USD","LU0348767384.USD","LU1251922891.USD","SG9999014674.SGD","BK1589","LU1997245094.SGD","LU2488822045.USD","LU2328871848.SGD","02268","BK1161","06978","LU1997245177.USD","LU1934453819.USD","LU2045819591.USD","BK1574","603259","LU2097828805.USD","BK1576","HK0000165453.HKD","LU0455707207.USD","06990","LU1770034418.SGD","LU1808992512.USD","BK0216","159992","LU2097828631.EUR","LU0320764599.SGD","LU0456842615.SGD","02359","LU2242644610.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426372","title":"北京亦庄牵头编制医疗器械、自动驾驶数据出境负面清单","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426372","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634426372?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 11:42","pubTimestamp":1778557320,"startTime":"0","endTime":"0","summary":"牵头制定两份新清单。在参与全市首批负面清单基础上，北京亦庄这次负责编制医疗器械、自动驾驶两大领域的负面清单，严格对标行业法律法规和国家标准，逐项细化场景、类别与量级，为市级清单迭代优化提供一线依据。李文峰表示，北京亦庄会把政策覆盖范围从亦庄组团扩展到整个亦庄新城，在国际医药创新公园、亦庄综保区等园区设服务窗口，医疗器械和自动驾驶清单发布后支持企业先行先试，让政策快落地、企业早受益。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-05-12/doc-inhxrfsq9953320.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-05-12/doc-inhxrfsq9953320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","159883","BK1100","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250452","title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250452","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634250452?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 10:55","pubTimestamp":1778554548,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药早盘涨超5%，截至发稿，涨2.38%，报15.49港元，成交额7370.89万港元。消息面上，5月11日，据再鼎医药官微消息，公司宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1588","BK4531","BK1119","BK4548","LU2488822045.USD","BK4526","09688","BK4585","BK4588","BK4139","ZLAB","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634256069","title":"中泰证券医疗器械2025及2026Q1总结：负面扰动逐步出清 持续看好创新驱动与全球化","url":"https://stock-news.laohu8.com/highlight/detail?id=2634256069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634256069?lang=zh_cn&edition=fundamental","pubTime":"2026-05-12 07:23","pubTimestamp":1778541837,"startTime":"0","endTime":"0","summary":"中泰证券主要观点如下：26Q1低耗与高耗表现相对较好，体外诊断逐步企稳。2026Q1收入端恢复稳健增长，利润端受到汇兑损失影响，表观利润有所下滑。检验量的负面影响基本于2025年末见底出清，价格层面，考虑集采节奏和终端收费调整进度，短期价格可能持续承压，有望于2026年下半年企稳。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","600918","BK0276","159883","BK1583","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}